Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 120,361 shares, a drop of 46.4% from the June 15th total of 224,716 shares. Approximately 1.3% of the company’s shares are short sold. Based on an average daily volume of 1,909,636 shares, the short-interest ratio is currently 0.1 days.

Avalon GloboCare Stock Performance

Shares of ALBT traded up $0.01 during mid-day trading on Friday, hitting $0.32. 295,548 shares of the company’s stock were exchanged, compared to its average volume of 3,971,371. The stock’s 50-day moving average is $0.33 and its 200-day moving average is $0.60. Avalon GloboCare has a fifty-two week low of $0.21 and a fifty-two week high of $4.74. The company has a market cap of $4.69 million, a price-to-earnings ratio of -0.09 and a beta of -0.03.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Avalon GloboCare from a “sell (e+)” rating to a “sell (e)” rating in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Avalon GloboCare currently has a consensus rating of “Sell”.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.